FDA warns quality of underground zalcitabine is poor; Roche expands premarketing access programs.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D004345:Drug Industry; D006801:Humans; D011786:Quality Control; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000592:standards* / Q000627:therapeutic use
D016047:Zalcitabine